Source comparison
Stacking AOD-9604 MOTS-C Fat Metabolism Research: Comparison
Primary Mechanism Beta-3 adrenergic receptor activation → HSL phosphorylation → lipolysis in adipocytes Mitochondrial AMPK activation → PGC-1α upregulation → enhanced fatty acid oxidation capacity Dual-pathway: substrate release (AOD-9604) + oxidative capacity
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Beta-3 adrenergic receptor activation → HSL phosphorylation → lipolysis in adipocytes
- Mitochondrial AMPK activation → PGC-1α upregulation → enhanced fatty acid oxidation capacity
- Dual-pathway: substrate release (AOD-9604) + oxidative capacity (MOTS-C) primed simultaneously
- Combination addresses both supply and demand sides of fat metabolism. Theoretically superior for research models
- Typical Rodent Dose
- 400–600 mcg/kg daily subcutaneous
- 3–7 mg/kg 3× weekly subcutaneous
- Both at midrange doses with 75-min staggered injection
- Dose ranges well-established; staggered timing critical for pathway alignment
- Metabolic Marker Changes (12-week rodent studies)
- 20–25% visceral fat reduction; no insulin sensitivity improvement
- 15–20% visceral fat reduction; 30–40% HOMA-IR improvement; 28% glucose uptake increase
- 35–45% visceral fat reduction; 35–50% HOMA-IR improvement; sustained RER reduction indicating lipid oxidation preference
- Combination produces additive fat loss with retained insulin sensitivity benefits. MOTS-C component drives metabolic health improvements
- Stability Post-Reconstitution
- 14 days at 2–8°C in bacteriostatic water pH 6.5–7.5
- 7 days at neutral pH; 21 days if reconstituted at pH 5.5–6.0 with 0.1% acetic acid
- Separate vials required; cannot be mixed due to pH incompatibility and aggregation risk
- Storage complexity increases with stacking. Dual reconstitution protocols add handling steps that increase contamination risk
- Evidence Quality
- Monash University Phase II data; multiple adipocyte culture studies; limited large-animal models
- Cell Metabolism publication; USC Longevity Institute preclinical trials; human pilot data emerging
- Single major stacking study (UCLA 2019); mechanism well-supported but replication data limited
- Monotherapy evidence strong for both compounds individually; combination data promising but requires independent replication before definitive claims